We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

35 hedge funds and large institutions have $7.12M invested in AIM ImmunoTech in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more capital invested

Capital invested by funds: $6.86M → $7.12M (+$259K)

15% less funds holding

Funds holding: 41 → 35 (-6)

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

77% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 13

Holders
35
Holders Change
-6
Holders Change %
-14.63%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
13
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors
Iowa
+$40.2K
2
VF
Virtu Financial
New York
+$11.4K
3
State Street
State Street
Massachusetts
+$10.9K
4
SWM
SeaCrest Wealth Management
New York
+$1.29K
5
CFN
Cordasco Financial Network
Florida
+$431

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$239K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$188K
3
BCM
Bridgeway Capital Management
Texas
-$47.4K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$45K
5
Morgan Stanley
Morgan Stanley
New York
-$42.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$2.11M -$42.4K -493 -2%
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.11M -$10.9K -127 -0.6%
BlackRock
3
BlackRock
New York
$878K -$4.91K -57 -0.7%
Renaissance Technologies
4
Renaissance Technologies
New York
$454K -$239K -2,773 -39%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$395K – – –
State Street
6
State Street
Massachusetts
$183K +$10.9K +127 +8%
BCM
7
Bridgeway Capital Management
Texas
$171K -$47.4K -550 -25%
Verition Fund Management
8
Verition Fund Management
Connecticut
$162K -$7.75K -90 -6%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$124K – – –
Northern Trust
10
Northern Trust
Illinois
$94K – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$89K -$188K -2,180 -72%
VF
12
Virtu Financial
New York
$54K +$11.4K +132 +35%
Cambridge Investment Research Advisors
13
Cambridge Investment Research Advisors
Iowa
$49K +$40.2K +467 New
Rockefeller Capital Management
14
Rockefeller Capital Management
New York
$42K – – –
SWM
15
SeaCrest Wealth Management
New York
$42K +$1.29K +15 +4%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$29K – – –
CAPTRUST Financial Advisors
17
CAPTRUST Financial Advisors
North Carolina
$21K – – –
LPL Financial
18
LPL Financial
California
$17K – – –
Bank of America
19
Bank of America
North Carolina
$16K -$86 -1 -0.7%
CB
20
Community Bank
New York
$14K – – –
Millennium Management
21
Millennium Management
New York
$14K – – –
TCM
22
Traynor Capital Management
Pennsylvania
$12K – – –
Wells Fargo
23
Wells Fargo
California
$11K -$1.29K -15 -13%
SSA
24
Schonfeld Strategic Advisors
New York
$11K -$258 -3 -3%
SFG
25
SNS Financial Group
Minnesota
$11K – – –
1
2

AIM Hedge Fund Activity: Q1 2022 in Review

35 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2022, worth a combined $7.12M — up 3.8% from $6.86M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of AIM and 2 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 3 added.

The largest buyer was Cambridge Investment Research Advisors, opening a new position worth an estimated $40.2K. The largest seller was Renaissance Technologies, cutting an estimated $239K.

  • 35 institutional investors held AIM ImmunoTech (AIM) as of Q1 2022, down from 41 in Q4 2021.
  • Funds reported $7.12M of AIM ImmunoTech stock for Q1 2022, up 3.8% quarter-over-quarter.
  • 2 funds opened new AIM ImmunoTech positions in Q1 2022 and 8 closed out, a net change of -6 holders.
  • The largest AIM ImmunoTech buyer in Q1 2022 was Cambridge Investment Research Advisors, an estimated $40.2K added.
  • The largest AIM ImmunoTech seller in Q1 2022 was Renaissance Technologies, an estimated $239K sold.

Based on aggregated 13F filings for Q1 2022.